Medical and health industry weekly report, industry news that deserves attention this week.
In recent years, innovations in the medical and health industry have continued to emerge and have developed into one of the most active industries, witnessing and accompanying the growth of innovative companies in this field, and bringing professional voices to the industry.
For this reason, the “Medical and Health Industry Weekly Report” was launched, which will be published regularly to provide readers with industry information from multiple perspectives such as capital, policy, finance, and new products.
Please check the weekly report of the medical and health industry on October 31. The industry weekly report contains the financing news reported by the “Venture Channel” in the medical and health sector this week, as well as other domestic and foreign industry news that deserve attention.
Performance announcement
-
Cansino Biological releases results for the first three quarters of 2020: revenue of 5,673,800 yuan, a year-on-year increase of 194.02%
Kangsino Biotech Co., Ltd. disclosed the 2020 third quarter report. The report shows that in the first three quarters of 2020, Cansino Bio will achieve an operating income of RMB 5.673 million, a year-on-year increase of 194.02%. Operating cost was 503,400 yuan, an increase of 284.16% from 131,100 yuan in the same period last year. The net profit loss attributable to shareholders of listed companies was 176 million yuan, an increase of 88.17% year-on-year. During the reporting period, the company’s research and development expenses were 177 million yuan, a year-on-year increase of 86.82%. The increase in operating income over the same period last year was due to the increase in the company’s vaccine component sales and technical service income during the reporting period.
-
Mindray Medical released its first three quarters of 2020 performance: revenue of 16.06 billion yuan, a year-on-year increase of 29.76%
Mindray Medical released the report for the third quarter of 2020, achieving revenue of 16.064 billion yuan in the first three quarters, a year-on-year increase of 29.76%; attributable to a listed company The shareholders’ net profit was 5.363 billion yuan, an increase of 46.09% year-on-year.
-
Fosun Pharma announces results for the first three quarters of 2020: revenue of 22.103 billion yuan, a year-on-year increase of 4.12%
Fosun Pharma announced its operating results for the three quarters ending September 30, 2020. In the first three quarters of this year, Fosun Pharma Group achieved operating income of RMB 22.103 billion, a year-on-year increase of 4.12%; realized net profit attributable to the parent of approximately 2.479 billion yuan, a year-on-year increase of 20.12%; during the same period, the net profit deducted from the parent was 2.060 billion. A year-on-year increase of 19.57%. Fosun Pharma’s main businesses are pharmaceutical manufacturing and R&D, medical device services, and medical services, accounting for 71.37%, 18.83%, and 9.69% of revenue respectively.
-
Lao People’s Pharmacy released its results for the first three quarters of 2020: revenue of 10.12 billion yuan, a year-on-year increase of 20.91%
Popular Pharmacy releases the third quarter report of 2020According to the report, the first three quarters achieved revenue of 10.12 billion yuan, a year-on-year increase of 20.91%; net profit attributable to shareholders of listed companies was 487 million yuan, a year-on-year increase of 23.60%.
-
Aier Ophthalmology released its performance report for the first three quarters of 2020: revenue of approximately 8.57 billion yuan, a year-on-year increase of 10.78%
Aier Ophthalmology released the report for the first three quarters of 2020, and the announcement shows January-September 2020 Realized revenue of 8565499836.12 yuan, a year-on-year increase of 10.78%; the net profit attributable to shareholders of listed companies was 154,460,354.77 yuan, a year-on-year increase of 25.6%. Among them, the net profit attributable to shareholders of listed companies in the third quarter was 869,990,509.74 yuan, a year-on-year increase of 62.34%. The increase in revenue was mainly due to the expansion of the company’s business scale and the upgrade of medical consumption.
-
Winner Medical released its performance report for the first three quarters of 2020: revenue of 9.523 billion yuan, a year-on-year increase of 205.36%
Winner Medical disclosed its performance report for the first three quarters. The listed company achieved operating income of 9.523 billion yuan, a year-on-year increase of 205.36%; net profit was 3.15 billion yuan, a year-on-year increase of 678.64%. In the third quarter, net profit was 2.118 billion yuan, a year-on-year increase of 1112.76%. The third quarter’s performance increased significantly, mainly because the self-developed cotton spunlace non-woven materials are widely used in surgical gowns, isolation gowns, protective clothing and other products.
-
Ping An of China announced its results for the first three quarters of 2020: an operating profit of 108.692 billionIncreased by 4.5%
Ping An of China announced the first three quarters performance report, the data shows that the group has achieved operations attributable to shareholders of the parent company The profit was 108.692 billion yuan, a year-on-year increase of 4.5%; the annualized operating ROE was 20.9%; but the net profit attributable to shareholders of the parent company was 103.41 billion yuan, a year-on-year decrease of 20.5%. Ping An said that due to the continuing impact of the epidemic, consumer demand in insurance and other financial sectors has recovered in the short term, but it is still shrinking compared to before the epidemic; at the same time, credit risks are rising and the quality of asset management services continues to be under pressure.
-
Huadong Pharmaceutical released the first three quarters of 2020 performance: revenue of 25.501 billion yuan, a year-on-year decrease of 7.7%
Huadong Medicine announced the first three quarters of 2020 performance report, achieving operating income of 25.501 billion yuan, a year-on-year decrease 7.7%; net profit attributable to shareholders of listed companies was 2.391 billion yuan, a year-on-year increase of 8.06%, and net profit attributable to shareholders of listed companies deducting non-recurring gains and losses was 2.031 billion yuan, a year-on-year decrease of 2.36%. Cash flow from operating activities The net amount was 1.902 billion yuan, a year-on-year increase of 109.21%. The three major sectors of pharmaceutical manufacturing, pharmaceutical commerce, and medical aesthetics all maintained a good development trend in the third quarter of this year, and achieved steady growth compared to the second quarter.
-
Nanjing Pharmaceutical released its results for the first three quarters of 2020: revenue of 29.074 billion yuan, a year-on-year increase of 4.99%
Nanjing Pharmaceutical announced that the company achieved operating income of 29.074 billion yuan in the first three quarters, an increase of 4.99% year-on-year; The net profit attributable to shareholders of listed companies was 283 million yuan, a year-on-year decrease of 3.96%; the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 237 million yuan, an increase of 2.09% year-on-year; basic earnings per share were 0.271 yuan.
-
Yunnan Baiyao released its first three quarters of 2020 performance: revenue of 23.931 billion yuan, a year-on-year increase of 10.56%
Yunnan Baiyao released its report for the third quarter of 2020. In the first three quarters, revenue was 23.931 billion yuan, a year-on-year increase of 10.56%; the net profit attributable to shareholders of listed companies was 4.253 billion yuan, a year-on-year increase of 20.08%.
-
Dashenlin released its first three quarters of 2020 performance: revenue was 10.492 billion yuan, a year-on-year increase of 30.49%
Dashenlin released a report for the third quarter of 2020. In the first three quarters, revenue was 10.492 billion yuan, a year-on-year increase of 30.49%; net profit attributable to shareholders of listed companies was 867 million yuan, a year-on-year increase of 55.90%.
Investment Financing
-
Fourier Smart received 100 million yuan in Series C financing
China Smart Rehabilitation EnterpriseFourier Smart has completed 100 million yuan C round of financing, this round of financing is funded by Yuan Jing Capital led the investment, followed by Qianhai Fund of Funds. This round of financing funds will be used for new product research and development, accelerate the improvement of the core product matrix of rehabilitation robots, improve the upstream and downstream platforms of the industrial chain, and promote the establishment of a rehabilitation ecosystem.
-
Zhenhe Technology completes over 1 billion yuan in Series E financing
It is reported that “Zhenhe Technology” has successfully completed a series E financing of over RMB 1 billion recently. This round of investment was led by the China State-owned Enterprise Structural Adjustment Fund (National Regulatory Fund), Taikang Asset, CCB Equity, Hillhouse Ventures, Suzhou Zhongmengxin, Huaxing Capital and other investment institutions followed the investment, and the old shareholder CICC Capital Subsidiary funds, Matrix China and other institutions continue to invest more. The funds raised in this round of financing will be used to further strengthen the R&D, innovation and introduction of Zhenhe tumor precision diagnostic products, accelerate the registration and application of its IVD products, and promote the deployment and expansion of Zhenhe market channels.
-
Henglu Biotechnology completes tens of millions of yuan in Pre-A round of financing
Henglu Biotechnology has completed a Pre-A round of financing of tens of millions of yuan. The investor is Huayao Capital, a well-known domestic investment institution. This round of financing will be mainly used for product development and market investment of Henglu Biotech in the field of human milk oligosaccharides (HMOs).
-
Paizhen Biotech completes B+ round of financing
It is reported that Guangzhou Pion true creaturesTechnology Co., Ltd. (PackGene or PackGene) completed a new round of B+ round of financing. The financing was led by Sequoia Capital China Fund, Decheng Capital followed the investment, Cathay Capital and Yuanhe Origin continued to participate in the investment. The financing will be mainly used to build GMP-level large-scale AAV production bases, expand GMP production workshops, increase production capacity, promote the development of new technologies and new processes for AAV vectors, and accelerate the industrialization of gene therapy at home and abroad.
-
Pharmaceutical completed tens of millions of yuan in Series A financing
Pharmaceutical B2B supply chain and operation service platform “A piece of medicine” has received tens of millions of yuan in A round Financing. This round of financing was led by Sequoia China Seed Fund, XinyuanCapital, Plum Blossom Angel Ventures, Dexun Investment Co-invested. He Yu, the company’s co-founder, said that this round of financing will be mainly used to strengthen supply chain capabilities, research and development, and expand teams, thereby promoting the integrated construction and integration of upstream and downstream supply chain systems.
-
Peptide Bio has completed nearly 100 million yuan in Series A financing
It is reported that “Peptide Bio” has recently completed a round of financing of nearly 100 million yuan. This round of financing was led by Sequoia Capital China Fund, and was jointly funded by Boyuan Capital, Taiyu Investment, Feifan Venture Capital and Cuihu Investment. The funds raised in this financing will be used to promote the company’s two first-in-class innovative drugs (First-in-class) and two biosimilar products in clinical applications and follow-up pipeline reserve projects.
-
Rosenbott completes tens of millions of Pre-A+ rounds of financing
Rosenbott (ROSSUM ROBOT), an intelligent surgical robot research and development company, has completed tens of millions of Pre-A+ rounds of financing. This round of investors is YaPreferential investment. This round of financing is mainly used to promote the further research and development and clinical trials of the company’s intelligent orthopedic surgical robot.
-
Health++ completes tens of millions of preA rounds of financing
“Health++” has completed the tens of millions preA round of financing led by Shunwei Capital earlier this year, with Echo Capital acting as the exclusive financial advisor. The funds raised in this round of financing will be used for technology research and development and channel construction, and to accelerate the early deployment of the company’s strategic project “making high-quality medical resource connectors”. Established in 2018, “Health++” is a health management service platform that improves the management level and operational efficiency of primary medical institutions by providing technical and operational services.
-
Yiying Medical received 35 million yuan in Series A financing
Jiangsu Yiying Medical Equipment Co., Ltd. received 35 million yuan in Series A financing, led by Fosun Pharma, and followed by Xiamen Saixin and its old shareholder Blue Bay Capital. This round of financing is mainly used for new product development and market development in the field of orthopedic surgical imaging equipment.
-
Yuanye Technology completed multi-million dollar Pre-A round of financing
Yrobot announced that it has received millions of dollars in Pre-A round of financing. Investors include BVBaidu Investment, Hillhouse Ventures, Linear Capital, Qiaobei Capital, The cornerstone of wisdom. Yuanye Technology was established in 2018 and mainly develops muscle outer armor products to serve people with mobility impairments, including middle-aged and elderly patients and stroke patients. This round of financing is mainly used to develop and iterate muscle outer armor products, promote localization of parts and components, conduct clinical tests in multiple medical institutions, apply for Class II medical device certification, and market expansion.
-
Genxi Biotechnology completes US$100 million Series C financing
Genxi Bio Technology Group (Genxi Bio) has completed a $100 million Series C financing. This round of financing was led by Wellington Management Company, OrbiMed and Morningside Ventures. New investors participating in this round also include Vivo Capital. Existing investors Temasek Holdings, Lilly Asia Ventures, OrbiMed and King Star Med LP also participated. The funds raised in this round will be used to accelerate the advancement of candidate products in the clinical stage to the next stage, and to further develop pre-clinical candidate product research and development activities.
-
Dipu Diagnostics completes Series A financing
Dipu Diagnostics completed Series A financing, led by CITIC Securities, Hangzhou Taiyu and Anji Haocheng participated in the investment. After the completion of this round of financing, Dipu Diagnostics will increase its investment in the research and development of high-end molecular diagnostic equipment, and increase the development of clinical application products in the fields of pharmacogenomics, tumor prevention and control, chronic disease management, infectious disease prevention and control, and birth defect prevention and control. Speed up the clinical certification and listing of its diagnostic products.
-
Weilizhibo completes 200 million RMB Series C financing
It is reported that “Weilizhibo” has recently completed 200 million yuan C round of financing. This round of financing was jointly led by Kunyao Group and Huafang Capital. The original shareholder Enran Ventures (under the “Nanjing Jiangbei New District” Its Ruiyoukang Investment Fund”), Waige Capital and the new investment institutions Guohong Venture Capital, Minglang Capital, New Silk Road Investment, Yangzijiang Fund, and Entropy Capital jointly participated in the investment.
-
Guichuang Medical completes more than US$50 million in Series C financing
The cardiovascular medical device R&D manufacturer Guichuang Medical completed more than US$50 million in Series C financing, led by Orbimed, Honghui Capital, SDIC Innovation and Zheshang Venture Capital continues to invest. Zhejiang Guichuang Medical Devices Co., Ltd. is a group enterprise that simultaneously develops, innovates, and industrializes high-end intracranial and peripheral intravascular high-end interventional medical devices.
-
Shanwaishan completed hundreds of millions of yuan in strategic financing
Blood purification equipment developerShanwaishan completed hundreds of millions of yuan in strategic financing, led by Hillhouse Ventures, followed by Xiangjiang Industry, Xiangjiang Liyuan Jianling, etc. Shanwaishan is a company specializing in blood purification A national high-tech enterprise that develops and produces equipment and hemodialysis consumables, as well as the construction and operation of chain dialysis centers.
Approved for listing
-
Livzon Group’s dantrolene sodium for injection was approved for listing
The Livzon Group issued an announcement stating that its subsidiary Livzon Pharmaceutical Factory Dantrolene Sodium for Injection received the “Drug Registration Certificate” and was approved to be listed for the prevention and treatment of malignant high fever. Livzon Group’s dantrolene sodium for injection is the first imitation in China. Malignant hyperthermia is a rare disease and a family-hereditary muscle disease. It is mainly caused by an abnormally high metabolic state of skeletal muscle triggered by volatile inhalation anesthetics and depolarizing muscle relaxants-succinylcholine.
-
Yangpu medical sample preservation solution passed FDA approval
The “Sample Preservation Solution IMPROVIRAL Viral Preservative Medium (VPM)” produced by Yangpu Medical has been approved by the FDA, and the company has entered the US “Viral Transport Medium (VTM)” sales list of manufacturers. This product is a medium used to transport and store nasopharyngeal swab samples or specific samples for a short time. It can be used for the collection, preservation and transportation of nasopharyngeal pathogen specimens such as influenza virus. It is matched with flocking sampling swabs use.
-
Sihuan Pharmaceutical’s botulinum toxin type A for injection was approved by the State Drug Administration
Sihuan Pharmaceutical releases announcement, The company’s exclusive agent and the Korean biopharmaceutical company Hugel, Inc.’s “Botoxin Type A for Injection (Letybo 100U, trade name: Le Tibao)” was officially approved by the State Drug Administration of China, becoming the first The four botulinum toxin type A approved to be marketed in China are also the first of its kind in Korea.
-
Jianyou shares busulfan injection was approved by FDA for drug registration
Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. issued an announcement stating that it has received a 60mg/10 mLANDA approval notice for busulfan injection issued by the US Food and Drug Administration (ANDA number: 212127). Indications: Applicable to combined cyclophosphamide as a pretreatment program before transplantation of allogeneic hematopoietic progenitor cells in chronic myeloid leukemia.
-
Hausen Pharmaceutical’s 4 generic generic drug Saxagliptin was approved for listing
Hausen Pharmaceuticals submitted the application for the marketing of 4 generic drugs Saxagliptin tablets Approved by the State Food and Drug Administration, it became the third domestic company to be approved for listing of this product after Aosaikang and Chia Tai Tianqing. The original research of saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor acquired by AstraZeneca from BMS. It was first approved by the FDA for listing in July 2009 and approved in April 2011. Enter China.
Policies and regulations
-
The National Development and Reform Commission issued a document: Including chronic disease Internet follow-up consultation fees into medical insurance
According to the website of the National Development and Reform CommissionIn order to implement the various arrangements and deployments of the Party Central Committee and the State Council on economic work in the second half of the year, and to further expand domestic demand, especially to effectively promote consumption, the National Development and Reform Commission and other 14 departments have issued the “Work Plan for Expanding Domestic Demand and Promoting Consumption in the Near Future”. The “Plan” mentioned that it will promote the acceleration of offline service consumption to “reach the Internet” and fully release the online economic potential. To improve the “Internet +” medical insurance payment policy. On the premise of ensuring the safety and quality of medical care, the cost of online follow-up visits for chronic diseases will be included in the scope of medical insurance payment.
Business Cooperation
-
The Baiyunshan Pharmaceutical General Factory of Guangzhou Pharmaceutical Group and WuXi AppTec signed a cooperation agreement for a category 1 innovative drug project
Guangyao Group’s Baiyunshan General Pharmaceutical Factory and WuXi AppTec’s subsidiary Shanghai WuXi AppTec New Drug Development Co., Ltd. signed a Class 1 New Drug Project Cooperation Agreement in Shanghai. The two parties reached a consensus on the cooperation of anti-tumor Class 1 new drugs. This signing marks the entry of the two parties into an all-round cooperation mode in the research and development of small molecule innovative drugs.
-
CStone Pharmaceuticals and EQRx have reached a global strategic cooperation on tumor immunotherapy drugs sugarizumab and CS1003
CStone Pharmaceuticals announced that it has reached a strategic cooperation with EQRx. According to the terms of the agreement, CStone Pharmaceuticals will receive a down payment of US$150 million, and the most Up to a milestone payment of US$1.15 billion and additional tiered royalties. EQRx will receive sugarizumab (anti-PD-L1 Anti-) and CS1003 (anti-PD-L1 monoclonal antibody) have exclusive commercialization rights in global markets except China, Taiwan, Hong Kong and Macau. CStone Pharmaceuticals will retain the development and commercialization rights of CS1003 in Greater China, and It will continue to explore its development prospects as a framework product for monotherapy and combination therapy.
-
Siludi Medicine and Haihe Medicine have reached a strategic cooperation on innovative analgesic drugs RMX1001 and RMX1002
Sidedi Medicine and Haihe Pharmaceutical have reached a cooperation on two innovative analgesic drugs, RMX1001 and RMX1002, Siddi Medicine will obtain the exclusive rights to develop, produce and commercialize these two new drugs in China. Both drugs have the potential to replace traditional non-steroidal anti-inflammatory drugs and become new analgesics, and have completed phase 1 clinical studies in China.
-
JD Health and Eisai China establish a joint venture company
JD Health and Eisai China jointly announced the establishment of a joint venture company—Jingyi in Jing’an District, Shanghai Weixiang (Shanghai) Health Industry Development Co., Ltd., the new company will be committed to creating a one-stop service platform to meet the needs of elderly users. At the same time, the People’s Government of Jing’an District, Shanghai, JD Health and Eisai China have also reached a tripartite strategic cooperation.
Editor: Dun Yuting
Pro is its WeChat official account